The CRISPR Gene Editing Market is set to grow at around 18.24% CAGR during 2022-27, predicts MarkNtel Advisors in their recent research study. It comprises a comprehensive analysis of the industry’s latest trends, developments, drivers, restraints, challenges, & opportunities, as well as its projected growth trajectory across different segments & geographies in the forecast years.
Further, the report also highlights the prominent aspects depicted in the form of diagrams, pie charts, tables, graphs, & other pictorial representations that would contribute to the market expansion in the future. Through this information, stakeholders will be able to comprehend the changing dynamics of the CRISPR Gene Editing Market and better plan & layout strategies in order to widen their visibility, product portfolio, & customer base and yield massive profits. In the report, the historical period considered is 2017-20, the base year 2021, and the forecast period, as cited above, is 2022-27.
Get A Free Sample Report PDF with Market Whole Graphs, Charts, and Statistics – https://www.marknteladvisors.com/query/request-sample/crispr-gene-editing-market.html
Key Highlights from the CRISPR Gene Editing Market Analysis –
➤This study is a compilation of key factors impacting the industry dynamics, including growth drivers, restraints, opportunities, challenges, and emerging & high-potential segments & geographies, among others.
➤Detail-driven, accurate, and reliable information associated with the latest trends in the industry to help stakeholders or investors make informed decisions before they make investments.
➤A comprehensive review of the leading companies in the CRISPR Gene Editing Market, comprising their profiles, recent developments, prominent business strategies, initiatives, and mergers & acquisitions, among other aspects.
➤Fund estimation put in by private firms & governments for the industry’s expansion, along with insights into each segment & geographic location, are also covered in this report.
CRISPR Gene Editing Market Key Driver –
In recent years, CRISPR gene editing demand has been driven by significant breakthrough scientific research across various dimensions to treat hereditary disorders. As per the research publication of the New England Journal of Medicine, 2020, CRISPR gene therapies depicted positive results for treating sickle cell anemia & beta-thalassemia. In addition, ongoing clinical trials for the gene correction in homo sapiens to treat genetic disorders further augmented the growth of the CRISPR Gene Editing market globally. For instance:
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease (CEDAR) clinical trial was posted in the USA, as of 2021, which is considered a first-in-human, single-arm study. The study is currently in Phase1/11 & is expected to be completed in 2026.
Key Trend in the CRISPR Gene Editing Market –
CRISPR gene technology has become the most utilized & versatile technology in functional genomics & crop breeding. Genome editing has the ability to create inheritable & predictable mutations in specific genomic sites to produce the desired results in crop production & cultivation.
Hence, this has gradually boosted the requirement for CRISPR gene technology for oil crops, food crops, feed crops, fiber crops, and ornamental crops to enhance the crop quality & market value of agricultural products. Further, various countries are adopting CRISPR gene editing technologies to modify crop production with different required characteristics. For instance:
-
In 2022, China approved the gene-edited crops, which have revolutionized the researchers to develop a wide array of wheat varieties resistant to fungal diseases & various others.
Therefore, the CRISPR gene-edited technologies opened up several new horizons for researchers to develop multiple crop varieties that have increased yields, resilience against climate change, and a better response to fertilizers.
CRISPR Gene Editing Market Segmentation:
The segmentation analysis section of the report focuses on the CRISPR Gene Editing Market performance across different segments & geographies, which can aid stakeholders in strategizing their investments in order to widen their visibility, product portfolio, & customer base and, in turn, generate significant revenue in the forecast years.
Market Divided into, By Product Type
-CRISPR Products
–Kits & Enzymes
–Libraries
–Design Tools
–Antibodies
–Others
-CRISPR Services
–gRNA Design & Vector Construction
–Cell Line and Engineering
–Screening Services
–Others
Market Divided into, By Application
-Agriculture
-Industrial
-Biomedical
–Gene Therapy
–Drug Discovery
–Diagnostics
-Others
Market Divided into, By End User
-Academic Institutions and Research Centers
-Biotechnology Companies
-Contract Research Organizations (CROs)
-Pharmaceutical & Biopharmaceutical Companies
To Get Complete Details of this Report Along with Facts and Figures – https://www.marknteladvisors.com/research-library/crispr-gene-editing-market.html
Geographically, the CRISPR Gene Editing Market expands across regions: –
-North America
-South America
-Europe
-Middle East & Africa
-Asia Pacific
Competitive Landscape:
Under this section, detailed information on company profiles, investments & revenue generated, strategic initiatives, geographical presence, and production or service capacities, among other aspects, have been examined. All insights into companies have been curated only after thoroughly studying their hold in the industry to help investors make informed decisions before investing.
-Abcam Inc.
-Applied StemCell Inc.
-Agilent Technologies Inc.
-Cellecta Inc.
-CRISPR Therapeutics AG
-Thermo Fischer Scientific Inc.
-GeneCopoeia Inc.
-GeneScript Biotech Corporation
-Horizon Discovery Group PLC
-Integrated DNA Technologies Inc.
-Merck KGaA
-New England Biolabs, Inc.
-Origene Technologies Inc.
-Rockland Immunochemicals Inc.
-Others (Synthego Corporation, ToolGen Inc., etc.)
Market Development By Leading Competitor –
?In 2021, Merck KgaA licensed its patented CRISPR-Cas9 technology to Cellecta for the development of next-generation treatments, which enables the researchers to advance treatments for inherited blood disorders, ophthalmologic, and oncological disorders, among others.
?In 2019, Thermo Fisher Scientific acquired Brammer Bio to increase its presence across the global market with the addition of Brammer Bio for the manufacturing of vectors for cell & gene therapies.
Have Any Enquires, Get Connect with Our Expertise – https://www.marknteladvisors.com/query/talk-to-our-consultant/crispr-gene-editing-market.html
Note: MarkNtel Advisors also offers customized reports where our dedicated analysts & domain-specific specialists strive to add value while curating tailored reports to cater to the varied requirements of clients so that they can make sound decisions before investing in the industry.
Get Connect For any Query at – +1 604 800 2671, +91 120 4278433
Email – sales@marknteladvisors.com
